Predilife S.A.

Paris Stock Exchange ALPRE.PA

Predilife S.A. Debt to Equity Ratio for the year ending December 31, 2023: 13.99

Predilife S.A. Debt to Equity Ratio is 13.99 for the year ending December 31, 2023, a 1,101.68% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Predilife S.A. Debt to Equity Ratio for the year ending December 31, 2022 was -1.40, a 57.39% change year over year.
Predilife S.A. Debt to Equity Ratio for the year ending December 31, 2021 was -3.28, a -186.41% change year over year.
Predilife S.A. Debt to Equity Ratio for the year ending December 31, 2020 was 3.79, a 294.65% change year over year.
Predilife S.A. Debt to Equity Ratio for the year ending December 31, 2019 was -1.95.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Paris Stock Exchange: ALPRE.PA

Predilife S.A.

CEO	Mr. Stephane Ragusa
IPO Date	Dec. 21, 2018
Location	France
Headquarters	39, Rue Camille Desmoulins
Employees	18
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Predilife S.A. develops and sells medical techniques and mathematical models. The company provides prevention and breast check-up tests. Its products include MammoRisk, a test for predicting the development of breast cancer based on the patient's individual risk; and DenSeeMammo, a breast density measurement software, as well as a medical device for the prediction of prostate cancer risk. Predilife S.A. was founded in 2004 and is headquartered in Villejuif, France.

Key trends

Past 5 years